Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib in Chinese patients with advanced solid tumors and FGFR2 fusion iCCA
CTR20191037Phase 3Terminated
- Sponsor
- Lunsheng Pharma
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of derazantinib in Nonhematologic neoplasms, intrahepatic cholangiocarcinoma (ICC), Hepatocholangiocarcinoma (HCC-CC), sponsored by Lunsheng Pharma. Started May 2019; status: terminated.
02
Drugs
derazantinib
03
Conditions
Nonhematologic neoplasmsintrahepatic cholangiocarcinoma (ICC)Hepatocholangiocarcinoma (HCC-CC)
Beyond the preview
Go deeper on CTR20191037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191037.